Is the Worst Behind Valeant Pharmaceuticals' Stock?
Valeant Pharmaceuticals' (NYSE: VRX) is knee-deep in a transformation that it hopes will allow it to regain its top-tier status with investors. The company's selling assets and funneling cash flow into debt prepayments to rein in its interest expense, and its third-quarter financials suggest it's making progress. Is this stock finally safe to buy?
Valeant's prior management employed an aggressive acquisition and marketing strategy that began unraveling after investigations revealed an all-too-close-for-comfort relationship with its specialty drug distributor and allegations of improper prescription fulfillment and reimbursement practices.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Bausch Health Companies Inc. Stock
€5.51
1.950%
